氨氯地平药物基因组学研究进展  

Research development on the pharmacogenetic of amlodipine

作　　者：阳喜定[1,2] 杨永玉[1] 阳国平[1,2] 

机构地区：[1]中南大学药学院,长沙410013 [2]中南大学湘雅三医院临床药理中心,长沙410013

出　　处：《中国临床药理学杂志》2013年第9期713-715,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家"重大新药创制"科技重大专项基金资助项目(2012ZX09303014-001);湖南省自然科学基金重点资助项目(11JJ2054)

摘　　要：氨氯地平为第3代二氢吡啶类钙拮抗剂,是临床上常用的治疗高血压和心绞痛的药物之一,其降压效果存在个体差异。这种差异是多种遗传因素和环境因素交互作用的结果。基因的多态性是造成药物疗效差异的主要因素之一。本文阐述其基因多态性对氨氯地平的药代动力学特征和降压疗效的影响。Amlodiping, a third - generation dihydropyridine calcium channel bloker, is widely prescribed for the management of hypertension and angina. The interindividual variation of antihypertensive efficacy has been observed, which is the result of a variety of genetic and environment factors. It has been proved that gene polymorphism was one of the main causes of the variation. In order to provide useful clinical information, we therefore want to summarize the effects of genetic polymorphisms on the pharmacokinetics and antihypertensive efficacy of amlodipine.

关 键 词：氨氯地平 药物基因组学 基因多态性 个体差异 

分 类 号：R972.4[医药卫生—药品] R969.1[医药卫生—药学]